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ARTICLE
Homozygous microdeletion of exon 5 in ZNF277
in a girl with specific language impairment
Fabiola Ceroni1, Nuala H Simpson2, Clyde Francks3,4, Gillian Baird5, Gina Conti-Ramsden6, Ann Clark7,
Patrick F Bolton8, Elizabeth R Hennessy9, Peter Donnelly2, David R Bentley10, Hilary Martin2, IMGSAC11,13,
SLI Consortium2,13, WGS500 Consortium2,13, Jeremy Parr11, Alistair T Pagnamenta2,12, Elena Maestrini1,
Elena Bacchelli1, Simon E Fisher3,4 and Dianne F Newbury*,2
Specific language impairment (SLI), an unexpected failure to develop appropriate language skills despite adequate non-verbal
intelligence, is a heterogeneous multifactorial disorder with a complex genetic basis. We identified a homozygous microdeletion of
21,379bp in the ZNF277 gene (NM_021994.2), encompassing exon 5, in an individual with severe receptive and expressive
language impairment. The microdeletion was not found in the proband’s affected sister or her brother who had mild language
impairment. However, it was inherited from both parents, each of whom carries a heterozygous microdeletion and has a history of
language problems. The microdeletion falls within the AUTS1 locus, a region linked to autistic spectrum disorders (ASDs). Moreover,
ZNF277 is adjacent to the DOCK4 and IMMP2L genes, which have been implicated in ASD. We screened for the presence of
ZNF277 microdeletions in cohorts of children with SLI or ASD and panels of control subjects. ZNF277 microdeletions were at an
increased allelic frequency in SLI probands (1.1%) compared with both ASD family members (0.3%) and independent controls
(0.4%). We performed quantitative RT-PCR analyses of the expression of IMMP2L, DOCK4 and ZNF277 in individuals carrying
either an IMMP2L_DOCK4 microdeletion or a ZNF277 microdeletion. Although ZNF277 microdeletions reduce the expression of
ZNF277, they do not alter the levels of DOCK4 or IMMP2L transcripts. Conversely, IMMP2L_DOCK4 microdeletions do not affect
the expression levels of ZNF277. We postulate that ZNF277 microdeletions may contribute to the risk of language impairments in a
manner that is independent of the autism risk loci previously described in this region.
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INTRODUCTION
Specific language impairment (SLI) is a common neurodevelopmental
disorder diagnosed in children with language abilities below age
expectations, given adequate educational opportunities and in the
absence of other medical conditions, such as hearing deficits or
intellectual disability. SLI affects 3–7% of preschool English-speaking
children.1 Twin and family studies support the role of a strong genetic
background in SLI,2 but a complex inheritance pattern suggests that
several loci and environmental factors contribute to the overall risk.
Although a diagnosis of SLI excludes the presence of other clinical
conditions that affect language, SLI presents co-morbidity with other
neurodevelopmental disorders, such as autism spectrum disorder
(ASD). Although ASD is characterized by an impaired communica-
tion, language skills can be highly heterogeneous and phenotypic
overlaps with SLI in the language domain have been debated. Some
studies report that a minority of adolescents with a history of SLI
show behavioral traits reminiscent of autism.3–5 Similarly, some find
that a subset of children with ASD exhibit language profiles
resembling SLI.6,7 However, others report qualitative differences that
can distinguish the performance of individuals with SLI or ASD in
language tests.8–10
Recent studies investigated whether the phenotypic similarities of
the language deficits may reflect potentially shared causes. An
example of functional link between SLI and ASD, in addition to
other neurodevelopmental disorders, is given by CNTNAP2: variants
in and disruptions of this gene are reported to be associated with
language endophenotypes in both SLI and ASD,11 suggesting that
CNTNAP2 might harbour susceptibility risk factors that could impair
language skills in distinct language-related disorders.
Submicroscopic copy number variations (CNVs) have been shown
to be an important source of susceptibility to psychiatric disorders,12
such as ASD, schizophrenia and bipolar disorder. Some CNVs are
recurrently observed across multiple neuropsychiatric conditions,13
sometimes with variable penetrance of the genes implicated,
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suggesting a pleiotropic effect. These findings support the hypothesis
that these CNVs can represent shared risk variants across different
types of neurodevelopmental diseases and might highlight common
genes and/or pathways.
Here, we describe a novel CNV case involving homozygous loss of
material from the ZNF277 gene, found in a child with SLI. This CNV
falls in the AUTS1 region of linkage to ASD (7q21-q32,
OMIM#209850).14–18 A fine mapping study of AUTS1 previously
reported association of ASD with SNPs in two genes that are proximal
to ZNF277, DOCK4 (dedicator of cytokinesis 4, OMIM#607679) and
IMMP2L (IMP2 inner mitochondrial membrane protease-like,
OMIM#605977).19 An additional investigation20 described a rare
microdeletion involving the DOCK4 and IMMP2L genes that
co-segregated with the presence of dyslexia in an extended family.
On the basis of prior reports of phenotypic and genetic overlaps
between SLI and ASD, and given the position of this homozygous
microdeletion, we hypothesized that ZNF277 may represent a
candidate gene for both disorders. Therefore, we went on to
investigate the frequency of ZNF277 microdeletions in cohorts of
individuals with SLI or ASD. Finally, we used quantitative PCR
(qPCR) techniques to further examine the effects of ZNF277
microdeletions on expression levels of genes in the AUTS1 region.
MATERIALS AND METHODS
Discovery pedigree
A genome-wide CNV screen of 512 individuals from families with SLI was
performed to investigate CNV burden in individuals with SLI. This study
utilized genome-wide SNP data from the Illumina Human OmniExpress
(v12.1) beadchip and identified CNVs within the Nexus,21 PennCNV22 and
QuantiSNP23 algorithms. A manuscript describing this larger data set is in
preparation. In the current manuscript, we describe an incidental finding from
these data: the identification of a homozygous microdeletion involving exon 5
of ZNF277 (NM_021994.2) (chr7:g111955948_111960100del, hg19). As this
microdeletion was in a homozygous form, we predicted that it might be
particularly deleterious to the individual and thus selected it for further study,
as described below.
The microdeletion was predicted to be present in a single child of a non-
consanguineous Caucasian family. The child had a clinical diagnosis of SLI.
She did not develop language skills until the age of 4–5 years. She appeared
sociable but was dependent on being shown what to do with toys. Her
thinking was slightly rigid but no other obvious autistic behaviors were
reported or observed. Her non-verbal intelligence was below average (perfor-
mance IQ¼ 75). She attended a special unit for speech and language impaired
children.
The proband had two siblings, an older brother and a younger sister. All
three children presented with a similar pattern of speech and language
impairment, which primarily affected the expressive domain. They all
presented with delayed word and phrase speech, unintelligible speech with
poor articulation and impaired word retrieval. However, the three children
differed in terms of the severity of their impairment and their non-verbal
attainment. The younger sister had a slightly higher non-verbal IQ than the
proband (PIQ¼ 94) and also had a diagnosis of SLI, although she appeared
less severely affected than the proband. The brother had a particularly high
non-verbal IQ (PIQ¼ 127) and although he was reported to have had an early
speech and language delay, he did not have a diagnosis of SLI. He did attend a
special educational unit and at 10 years of age he had a significant verbal
performance discrepancy and impaired sentence recall. Both parents reported a
family history of speech or language problems.
Validation in the discovery pedigree
qPCR using iQ SYBR-green Supermix (Bio-Rad, Hercules, CA, USA) and four
primer pairs across the predicted CNVand the surrounding region was used to
validate the presence of the microdeletion and to examine co-segregation in
the discovery pedigree. Primer sequences are available on request. All the
members of the family were analyzed by qPCR, except for the sister, for whom
insufficient DNA was available. The sister was instead tested using a PCR assay
with primers spanning the ZNF277 microdeletion breakpoints, as described for
the screening of the larger cohort below. For each sample, qPCRs were set up
in triplicate and compared against a control gene (ZNF423) and a control
subject. The number of copies of each amplified fragment was calculated using
the 2DDCt method.24
The boundaries of the ZNF277 microdeletion were determined by Sanger
sequencing using primers flanking the predicted deletion boundaries.
Screening of larger cohorts
Primers spanning the ZNF277 microdeletion breakpoints, which generated a
shortened product in the presence of the microdeletion, were used for a PCR-
based screening of three separate cohorts: a cohort of families containing
individuals with SLI, a cohort of families containing individuals with ASD and
a control cohort. A second primer pair that amplifies exon 5 of ZNF277, giving
a product only when the allele is not deleted, was subsequently used to test
whether the identified microdeletions were in the heterozygous or homozygous
form.
The SLI screening cohort consisted of DNA from 1234 individuals from 322
families (545 parents, 318 SLI probands and 371 siblings). This cohort
included the 512 individuals who comprised the CNV study but included
many additional SLI subjects (144 additional probands) and their family
members (550 individuals). All families formed a part of the SLI Consortium
cohort, which has previously been described in detail.25–28 In short, these
British nuclear families were ascertained on the basis of at least one child who
had expressive or receptive language skills Z1.5 standard deviations (s.d.)
below the normative mean for their chronological age and WISC Perceptual
Organisation Index (a composite score of the non-verbal subtests Picture
Completion, Picture Arrangement, Block Design and Object Assembly) of
477.5 (1.5 s.d. below that expected for their age).
The ASD cohort consisted of DNA from 1021 individuals from 252 families
(454 parents, 412 affected children and 155 siblings) and formed part of the
International Molecular Genetic Study of Autism Consortium (IMGSAC)
cohort, which has previously been described.16 The families were collected
from different countries (UK, Netherlands, France, USA, Germany, Denmark
and Greece) and were predominantly Caucasian (92.5%). In short, this cohort
consists of multiplex ASD families in which at least one child meets a clinical
diagnosis of ASD under the Autism Diagnostic Interview and/or Autism
Diagnostic Observation Schedule (ADOS) or ADOS generic.
The control cohort consisted of DNA from 224 non-related UK Caucasian
blood donors from the ECACC Human Random Control (HRC) panel (http://
www.hpacultures.org.uk/products/dna/hrcdna/hrcdna.jsp). In addition, we had
access to sequence data from 130 unrelated Caucasian samples through an in-
house project at the Wellcome Trust Centre for Human Genetics – the 500
Whole-Genome Sequences Project (WGS500 Consortium29).
We used the two-tailed Fisher’s exact test (1 degree of freedom) to test
whether the allelic frequency of ZNF277 microdeletions was significantly
different between SLI probands and control individuals.
Gene expression evaluation
RNA samples were not available for the discovery individuals. We therefore
chose to examine expression levels of ZNF277, DOCK4 and IMMP2L by qPCR
in cDNA derived from lymphoblastoid cell lines from 10 individuals belonging
to four ASD families, 5 of whom carried a heterozygous ZNF277 microdele-
tion, and the expression level of ZNF277 in cDNA derived from blood from
two individuals from a single Dutch multiplex ASD family previously
described by Pagnamenta et al.20 with an IMMP2L_DOCK4 microdeletion
(chr7:g.110876742_111470446del, hg19). The housekeeping gene GUSB
(NM_000181.3) was used as a normalizer and expression levels were
normalized against a control individual. The 2DDCt method was applied to
estimate the difference in the expression of the three genes between the
samples.24 Statistical significance was calculated with the Student T-test,
assuming unequal variance between the two independent sample groups for
the expression analysis.
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RESULTS
Identification and validation of a homozygous microdeletion of
exon 5 in ZNF277
During a CNV analysis of SNP array data, a female patient with a
diagnosis of SLI was found to carry a novel homozygous microdele-
tion within the gene ZNF277. The microdeletion removes exon 5 of
the ZNF277 gene, causing a frame-shift mutation and introducing a
premature stop codon in exon 7 (NM_021994.2). Given the like-
lihood of non-sense-mediated mRNA decay, this homozygous micro-
deletion would thus be predicted to result in a complete lack of
functional protein in the affected individual.30
qPCR of available family members in this pedigree demonstrated
that one copy of the microdeletion was transmitted to the proband
from each parent, who were both heterozygotes and reported to have
language problems in their childhood: the father had speech
impairment and the mother had dyslexia. However, the microdeletion
was not transmitted to the proband’s brother, who presented with an
early expressive speech and language impairment but did not have a
diagnosis of SLI (Figure 1a). Insufficient DNA was available for the
qPCR assay in the proband’s sister.
The predicted microdeletion included only three SNP probes
(rs11769219, rs4727766 and rs7802828) and had a minimum
predicted size of 4153 bp. At the time of detection, there were no
overlapping deletions described in the Database of Genomic Variants
(DGV)31,32 (January 2012). Subsequently, one larger, overlapping
heterozygous loss, was described in a HapMap female control sample
(NA12156) (DGV, February 2013). A similar size microdeletion was
observed in an in-house sequencing database at the Wellcome Trust
Centre for Human Genetics in a heterozygous form (1/130 samples of
the 500 Whole-Genome Sequences Project (WGS500 Consortium29))
Figure 1 Molecular characterization of the ZNF277 microdeletion in the discovery pedigree. (a) On the left, the results from the qPCR, on the right the
discovery pedigree, where black indicates diagnosis of SLI and grey indicates language problems. (b) On the right, the results of PCR across the
microdeletion breakpoints: only the allele with the microdeletion can be amplified and visualized as a band of 466bp in the parents and in the proband. On
the left, amplification of exon 5 of ZNF277 indicates the presence of at least one allele without the microdeletion. In both gels, 1 kb Plus DNA ladder was
loaded at the extremities. (c) Sequence electropherograms from the PCR products spanning the microdeletion in ZNF277. The rectangle indicates the
genomic position of the microdeletion in ZNF277. The 2 bp (TC), common to both ends, are delimited by dotted lines and circled in the reference
sequence. bp, base pair, PCR, polymerase chain reaction, qPCR, qPCR.
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allowing the accurate detection of the breakpoint boundaries which
lie in two LINE elements, L2c and L1M4. Sanger sequencing validated
the boundaries in the discovery individual (chr7:g.111941769_
111963147, hg19: 21 379 bp) and confirmed the presence of the
microdeletion in the parents and proband but not in either of the
siblings (Figures 1b and c).
Detection of the ZNF277 heterozygous microdeletion in the SLIC
and IMGSAC cohorts
In addition to the discovery family, another 1229 individuals were
screened giving a total cohort size of 322 families (1234 individuals)
affected by SLI (545 parents, 318 probands and 371 siblings). The
screening led to the identification of 16 additional individuals with
the ZNF277 microdeletion in a heterozygous form, 5 of whom were
probands (allelic frequency 0.8%), 6 parents (allelic frequency 0.6%)
and 5 siblings (allelic frequency 0.7%) (Figure 2), giving an allelic
frequency of 0.8% in the entire cohort (20/2468 chromosomes).
Across all SLI probands (ie independent cases including the discovery
proband), the allelic frequency of microdeletions was therefore 1.1%
(7/636 chromosomes).
In contrast, the microdeletion was observed in the heterozygous
form in 1 of 130 unrelated samples in our in-house sequencing cohort
(allelic frequency 0.4%) and 2 of 224 ECACC control individuals
(allelic frequency 0.4%) giving a control population allelic frequency
of 0.4% (3/708 chromosomes).
Screening of 252 ASD families (1021 individuals) identified
heterozygous ZNF277 microdeletions in 4 ASD families. Four
mothers carried the microdeletion (allelic frequency 0.4%) and it
was inherited by three affected children (allelic frequency 0.4%) giving
a frequency of 0.3% (7/2042 chromosomes) across the entire cohort.
All of the ASD families were ascertained as multiplex pedigrees and
thus included more than one affected child. Unlike the SLI families, in
many cases, there was no single designated proband within the family
units. All three ASD cases who inherited the microdeletion had
affected siblings who did not inherit the microdeletion rendering the
derivation of an objective proband frequency problematic.
The deletion of exon 5 in ZNF277 causes a decrease in the mRNA
expression
In order to investigate the effect of the ZNF277 microdeletion and its
relationship to a nearby IMMP2L_DOCK4 microdeletion indepen-
dently described in an autistic family in a previous publication20
(Figure 3a), we assessed the effects of ZNF277 microdeletion on the
expression of ZNF277, DOCK4 and IMMP2L. Conversely, we also
assessed the effect of IMMP2L_DOCK4 microdeletions on the
expression of ZNF277. In its heterozygous form, the ZNF277
microdeletion decreased the expression of the entire ZNF277 tran-
script (P¼ 0.035) but did not significantly alter the expression of
DOCK4 or IMMP2L (Figure 3b). Similarly, the microdeletion within
DOCK4 and IMMP2L did not decrease the ZNF277 expression
(Figure 3c). Note that this deletion has previously been shown to
decrease the expression level of DOCK4.20
DISCUSSION
In this study, we identified a novel homozygous microdeletion of
exon 5 of the ZNF277 gene in a child with SLI. Screening of an
additional 321 SLI families indicated that the allelic frequency of
ZNF277 microdeletions was more than twice that was observed in
control cohorts (1.1 vs 0.4%), although the rarity of the microdeletion
meant that this difference did not reach significance when examined
with a two-tailed Fisher’s exact test (P¼ 0.206).
Given prior observations of phenotypic and genetic overlaps
between SLI and autism, as well as the genomic position of the
ZNF277 gene within a known ASD risk locus, we postulated that the
disruption of this gene may be relevant for both disorders. However,
screening of a cohort of ASD multiplex families found that the
frequency of ZNF277 microdeletions in individuals with autism was
similar to that observed in controls. The ZNF277 microdeletion that
we describe was not documented in the DGV, possibly because of the
small number of standard array SNPs contained within the deleted
segment. However, we specifically searched Supplementary Data from
CNV studies of ASD and found that the microdeletion had been
previously characterized during a CNV screen of the Simons Simplex
Collection33 and occurred at a frequency of 0.3% (6/2248
chromosomes). This figure matches with that observed in our ASD
cohort, supporting the current data set and reinforcing our
conclusion that the ZNF277 microdeletion does not contribute to
ASD susceptibility.
In the SLI families where DNA of both parents was available, we
observed that none of the ZNF277 microdeletions was de novo and
that, in many cases, the segregation with language impairment was
Figure 2 Pedigree of the SLIC families carrying the ZNF277 microdeletion.
Black filling indicates full diagnosis of SLI.
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incomplete. In three families, the microdeletion was not inherited by
the proband, whereas in another three families, the microdeletion was
inherited by unaffected siblings (Figure 2). Furthermore, although
sample sizes of individuals carrying the deletion were small, we did
not observe any correlation between the presence of the deletion and
any language-related phenotypes investigated (Supplementary
Table 1). These data suggest that the heterozygous copy loss of exon
5 of ZNF277 may represent a risk factor rather than a highly
penetrant variant, whereas the homozygous copy loss appears to have
a greater impact on the SLI susceptibility. In neurodevelopmental
disorders, it is hypothesized that multiple common and rare variants
act in concert to determine the phenotype in a complex manner.
Under this hypothesis, it is perhaps not surprising to find risk variants
in both affected and unaffected family members, or to observe
transmission to only a subset of affected individuals of the family.
Such findings are consistent with a multigenic threshold model.34
Some variants may be highly penetrant while others may be
individually insufficient to cause the disorder, but they may
Figure 3 IMMP2L, DOCK4 and ZNF277 transcription levels in individuals with ZNF277 microdeletion. ZNF277 transcription levels in individuals with
IMMP2L_DOCK4 microdeletion. The graph shows the ratio of IMMP2L, DOCK4 and ZNF277 transcript levels, normalized using GUSB as a reference.
(a) Schematic representation showing ZNF277, DOCK4 and IMMP2L loci with respect to chromosome 7. The bars underneath show the chromosomal
position of the two types of microdeletions that were analyzed. (b) the ratio has been calculated as an average of five samples for each group of individuals,
belonging to four ASD families: ‘not-del’ indicates the group of individuals with two wild-type copies of ZNF277, ‘del’ the group of individuals with the
heterozygous ZNF277 microdeletion. Two fragments were tested for the ZNF277 transcript: exons 1–2 (which lies outside of the microdeletion) and exons
3–5 (which encompasses the microdeletion). The expression pattern for the fragments was decreased in both cases when compared with individuals without
the CNV, whereas in exon 5 it was significantly lower (P¼0.035). Bars indicate the standard errors. (c) The ratio of ZNF277 expression has been
calculated for two individuals of a family with an IMMP2L_DOCK4 microdeletion: the father, who has two normal copies of IMMP2L and DOCK4, and the
mother, who carries the IMMP2L_DOCK4 deletion.
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combine with other risk loci and/or environmental factors to cross the
risk threshold. Even well-established risk loci for autism, ID,
schizophrenia and other neurodevelopmental syndromes provide
examples of imperfect segregation, as shown by exonic CNVs
in NRXN1,35 missense mutations in SHANK2,36 rare sequence
and structural variants in CNTNAP2,37,38 microdeletions and
microduplications at 16p11.2.39–41
Given these data, some researchers propose a ‘dual-hit’ model.42
Under such a hypothesis, the phenotypic effects of copy number
events, even those of high penetrance, may be modulated by a second
independent genetic ‘insult’ which may take the form of an additional
CNV or a rare coding mutation. Support for this model comes from
studies of single language-impaired cases43 and larger cohorts of
individuals with ASD44,45 or particular microdeletion/duplication
syndromes.42,46–48 In the current discovery family, there were no
obviously co-segregating second hits. A rare duplication of 72Kb was
observed to occur only in the proband (chr2:g.41263841-
41336618dup, hg19 – Supplementary Table 2) and a novel 9Kb
deletion was observed in the mother and sister (chr2:g.125099924-
125109738del, hg19 – Supplementary Table 2). However neither of
these events affects any coding sequence. Larger or more in-depth
studies would therefore be required to further investigate possible
genetic modulators of ZNF277 microdeletions. It is conceivable that
the phenotypic variability associated with heterozygous ZNF277
microdeletions might be modulated by a combination of pathogenic
single-nucleotide variants in other genomic locations, small changes
in regulatory regions or other factors beyond the scope of this study.
We found that the heterozygous microdeletion of exon 5 in ZNF277
does not affect the expression of autism candidate genes IMMP2L and
DOCK4. Similarly, a microdeletion involving the 30 end of DOCK4
(exons 27–52), a gene which lies head-to-head with the ZNF277 gene,
and the first three exons of IMMP2L, decreases the expression level of
DOCK4 but not ZNF277. Taken together, these data suggest that
ZNF277 microdeletions may have a role in SLI susceptibility that is
distinct from the autism risk loci described in the AUTS1 region.
ZNF277 is an evolutionary conserved zinc finger gene with 12
exons.49 It is expressed in several tissues, including the brain,
particularly in the neocortex and hippocampus in early mid-fetal
development.50 Although the function of ZNF277 has not been
studied in humans, the mouse Zfp277 gene, which shows 480%
homology to the human gene at the amino-acid level, has been
implicated in the epigenetic regulation of cellular memory.51
Zfp277/ mice were born healthy and fertile, indicating that the
knockout is not lethal,51 consistent with our finding of viability for
humans with no functional ZNF277. Interestingly, the Zfp277 protein
directly interacts with Bmi-1, a key component of the Polycomb
Repressor Complex. This complex has an important role in the
maintenance of adult stem cells from numerous tissues, including the
central nervous system.52,53
Sequencing of the breakpoints in the discovery individual demon-
strated that the breakpoint boundaries lie in two LINE elements, L2c
and L1M4. L2c (chr7:g.111941666_111941883, hg19, strand þ )
belongs to the L2 LINE family and L1M4 (chr7:g.111961275_
111963848, hg19, strand ) to the L1 LINE family, which promote
structural variation through non-allelic homologous recombination.
BLAST alignment of the entire sequence of these two elements did not
reveal extended homology between them. However, sequencing of the
breakpoints revealed 2 bp microhomology at the junctions, suggesting
that this deletion may to be generated through a microhomology-
mediated repair mechanism.54 In conclusion, we propose that the
disruption of ZNF277 may contribute to SLI in a complex genetic
model. We further hypothesize that this risk is distinct from the
autism risk loci as previously described in this region. Further studies
will be required to replicate these findings and characterize the
function of the human protein ZNF277, clarifying its potential
implication in language development.
NOTE ADDED IN PROOF
During the proof-editing stage of the manuscript, we noted that a
deletion of the same size had also been reported in the most recent
release of DGV (evs2656841) (DGV, January 2014). These data again
supported the expected frequencies found throughout our study
(evs2656841 frequency¼ 0.35% – 8 losses in 2302 chromosomes
(1151 individuals)).
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